1333331-66-0

Upstream product

• 1333331-62-6 C₃₇H₅₃N₃O₉ 
• 1333331-60-4 C₃₄H₄₉N₃O₉ 
• 1333331-58-0 C₄₀H₆₃N₃O₉Si 
• 1255212-85-1 tert-butyl((2R,3R)-2-((tert-butyldimethylsilyl)oxy)-4-(((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)amino)-3-methylbutyl)(methyl)carbamate 
• 1255213-22-9 C₁₂H₁₃NO₅ 
• 625-31-0 (S)-4-penten-2-ol 
• 1333331-64-8 tert-butyl (((2S,8R,9R)-11-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,9-dimethyl-14-nitro-12-oxo-2,3,6,8,9,10,11,12-octahydrobenzo[b][1,9,5]dioxaazacyclotetradecin-8-yl)methyl)(methyl)carbamate 
• 1333331-55-7 C₃₅H₅₄FN₃O₈Si 

Downstream Products

• 1353557-47-7 2-fluoro-N-(((2S,8R,9R)-11-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,9-dimethyl-12-oxo-14-(3-phenylureudo)-2,3,4,5,6,8,9,10,11,12-decahydrobenzo[b][1,9,5]dioxaazacyclotetradecin-8-yl)methyl)-N-methylbenzenesulfonamide 
• 1255397-71-7 3-[(2S,8R,9R)-11-((S)-1-hydroxypropan-2-yl)-2,9-dimethyl-8-[(N-methyl(4-fluorobenzene)sulfonamido)methyl]-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea 
• 1353557-48-8 (2S)-2-[(2S,8R,9R)-2,9-dimethyl-8-[(N-methyl(4-fluorobenzene)sulfonamido)methyl]-12-oxo-14-[(phenylcarbamoyl)amino]-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-11-yl]propyl 2,2-dimethylpropanoate 
• 1353557-50-2 3-[(2S,8R,9R)-11-[(S)-1-(methoxymethyl)propan-2-yl]-2,9-dimethyl-8-[(N-methyl(4-fluorobenzene)sulfonamido)methyl]-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea 
• 1353557-51-3 N-(((2S,8R,9R)-11-((S)-1-azidopropan-2-yl)-2,9-dimethyl-12-oxo-14-(3-phenylureudo)-2,3,4,5,6,8,9,10,11,12-decahydrobenzo[b][1,9,5]dioxaazacyclotetradecin-8-yl)methyl)-4-fluoro-N-methylbenzenesulfonamide 
• 1353557-52-4 N-(((2S,8R,9R)-11-((S)-1-aminopropan-2-yl)-2,9-dimethyl-12-oxo-14-(3-phenylureudo)-2,3,4,5,6,8,9,10,11,12-decahydrobenzo[b][1,9,5]dioxaazacyclotetradecin-8-yl)methyl)-4-fluoro-N-methylbenzenesulfonamide 
• 1353557-53-5 3-[(2S,8R,9R)-2,9-dimethyl-8-[(N-methyl(4-fluorobenzene)sulfonamido)methyl]-11-[(S)-1-(methylamino)propan-2-yl]-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea 
• 1353557-67-1 C₃₇H₅₀N₄O₆ 
• 1353557-68-2 2-methoxyethyl (((2S,8R,9R)-11-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,9-dimethyl-12-oxo-14-(3-phenylureido)-2,3,4,5,6,8,9,10,11,12-decahydrobenzo[b][1.9.5]dioxaazacyclotetradecin-8-yl)methyl)(methyl)carbamate 
• 1353557-64-8 tert-butyl (((2S,8R,9R)-11-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,9-dimethyl-12-oxo-14-(3-phenylureido)-2,3,4,5,6,8,9,10,11,12-decahydrobenzo[b][1.9.5]dioxaazacyclotetradecin-8-yl)methyl)(methyl)carbamate 
• 1403479-58-2 (2S)-2-[(2S,8R,9R)-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfonamido]methyl}-12-oxo-14-[(phenylcarbamoyl)amino]-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxazacyclotetradecin-11-yl]propyl 4-methylbenzene-1-sulfonate 
• 1403479-55-9 3-[(2S,8R,9R)-11-[(2S)-1-[(tert-butyldimethylsilyl)oxy]propan-2-yl]-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfonamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxazacyclotetradecin-14-yl]-1-phenylurea 
• 1403479-53-7 3-[(2S,8R,9R)-11-[(2S)-1-methoxypropan-2-yl]-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfonamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxazacyclotetradecin-14-yl]-1-phenylurea 
• 1403479-51-5 3-[(2S,8R,9R)-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfonamido]methyl}-12-oxo-11-[(2S)-1-(pyridin-3-yloxy)propan-2-yl]-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxazacyclotetradecin-14-yl]-1-phenylurea 

Relevant academic research and scientific papers

Diversity-oriented synthesis yields a novel lead for the treatment of malaria

Here, we describe the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites. Screening a novel compound collection created using diversity-oriented synthesis (DOS) led to the initial hit. Structure-activity relationships guided the synthesis of compounds having improved potency and water solubility, yielding a subnanomolar inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma. This compound is available via the molecular libraries probe production centers network (MLPCN) and is designated ML238.

MACROLACTAM COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA

The present invention relates to a macrolactam compound, and methods for treating a subject with malaria using the macrolactam compound, represented by the following structural formula (l), wherein the values and preferred values of the variables are defined herein.

Diversity-oriented synthesis of 13- to 18-membered macrolactams via ring-closing metathesis

An efficient build/couple/pair approach to diversity-oriented synthesis was employed to access several structurally complex macrolactams. In this paper, we describe the successful evaluation of ring-closing metathesis toward the systematic generation of skeletal diversity. By appropriately varying the nature and chain length of the alkenol fragment, a diverse collection of 13- to 18-membered macro-lactams were obtained.